ENSAYO CLÍNICO, ABIERTO, DE GRUPOS PARALELOS, FASE III, PARA VALORAR EL EFECTO ANTIPROTEINÚRICO DE LOS DERIVADOS DE LA VITAMINA D EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA E INSUFICIENCIA DE VITAMINA D.

An open label, parallel groups, phase III, clinical trial to assess the antiproteinuric effects of the vitamin D derivates in patients with chronic kidney disease and vitamin D insufficiency. - Nefrovid2010

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-024023-25-ES

Enrollment

174

Registered

2011-07-08

Start date

2011-09-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.0 Level: SOC Classification code 10038359 Term: Renal and urinary disorders System Organ Class: 10038359 - Renal and urinary disorders

Interventions

Trade Name: Zemplar Product Name: zemplar Product Code: 68022 Pharmaceutical Form: Capsule, soft INN or Proposed INN: D00930 CAS Number: 131918-61-1 Other descriptive name: PARICALCITOL Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 174 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Secondary

Measure	Time frame
Timepoint(s) of evaluation of this end point: Está establecido en el apartado anterior para cada una de las variables.	—

Countries

Spain

Contacts

Public ContactClinical Trial Unit

Hospital Universitario de Canarias

a.aldea@gmail.com+34922678115

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026